Ratings New Horizon Health Limited OTC Markets

Equities

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

Apr. 08	New Horizon Health Limited Announces Board Appointments	CI
Mar. 28	New Horizon Health Limited Announces Delay in Publication Annual Results for the Year Ended December 31, 2023	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 99.04 times its estimated earnings per share for the ongoing year.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
NEW HORIZON HEALTH LIMITED	-.--%	812M		-
BIOMÉRIEUX	-6.61%	12.1B		B+
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-4.07%	8.14B		B-
DIASORIN S.P.A.	+6.22%	5.72B		B
LANTHEUS HOLDINGS, INC.	+28.13%	5.51B		C
10X GENOMICS, INC.	-59.44%	2.72B		D+
ANDON HEALTH CO., LTD.	+8.04%	2.59B	-	-
VITROLIFE AB	-7.24%	2.34B		B-
MYRIAD GENETICS, INC.	+21.84%	2.11B		C
GUANGZHOU WONDFO BIOTECH CO.,LTD	-8.15%	1.79B		D+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality